TabsDetailsBasic DetailsDate Posted: Friday, January 24, 2020Status: CompleteMedical Product: atezolizumab, avelumab, durvalumab, ipilimumab, nivolumab, pembrolizumabHealth Outcome(s): Bell’s palsyGuillain-Barré syndromeDescription: In this request, we examined the number of checkpoint inhibitor users with a diagnosis of Guillain-Barré syndrome (GBS) or Bell's palsy after drug initiation in the Sentinel Distributed Database (SDD). We also examined the time to GBS or Bell's palsy diagnosis after checkpoint inhibitor initiation among users in the SDD.We used data from March 1, 2011 to June 30, 2018 from 17 Data Partners contributing to the SDD in this report. We distributed this request to Data Partners on September 25, 2018. Read More Deliverables (1)Sentinel Modular Program Report: Time Until Guillain-Barré Syndrome or Bell's Palsy Diagnosis following Initiation of Checkpoint Inhibitor TreatmentAdditional InformationAdditional DetailsFDA Center: CDERTime Period: March 1, 2011 - June 30, 2018Study Type: Modular ProgramAssessment Type: Exploratory AnalysesPopulation / Cohort: All individualsData Sources: Sentinel Distributed Database (SDD)